Mode
Text Size
Log in / Sign up

Residual global μQFR assessment associated with 3-year MACE risk in acute coronary syndrome patientsBetter Heart Maps Predict Long-Term Survival

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider residual global μQFR for risk stratification in ACS, noting the post hoc design limits causal conclusions.

This study represents a post hoc analysis of a randomized controlled trial involving 2,428 acute coronary syndrome patients. The population included individuals with ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina. Participants underwent residual global μQFR assessment to stratify risk into high-risk versus low-risk groups.

Over a follow-up duration of 36.0 months, the primary outcome of 3-year major adverse cardiac events occurred in 21.2% of the high-risk group compared to 10.4% in the low-risk group among n = 407 high-risk patients. This difference yielded an adjusted HR of 1.53 with a 95% CI: 1.10-2.13; P = 0.01. When excluding periprocedural myocardial infarction, 3-year MACE rates were 16.2% versus 7.8%, respectively, with an adjusted HR of 1.72 (95% CI: 1.17-2.53; P = 0.006).

In patients with low residual ischemia, QFR-guided PCI was associated with 8.8% MACE versus 11.9% for angiography-guided PCI (HR: 0.73; 95% CI: 0.55-0.97). Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The primary limitation is the post hoc analysis design, which restricts causal inference.

While residual global μQFR appears to be a robust angiographic index for long-term risk stratification, the evidence remains associative. Clinicians should recognize that these results reflect associations rather than proven causation regarding intervention efficacy.

Imagine walking into a doctor's office with chest pain. The doctor looks at your heart's main pipes on a screen. They see a blockage and clear it with a stent. You feel better immediately. But what happens in the next three years?

That is the big question.

Millions of people suffer from acute coronary syndrome. This includes heart attacks and severe chest pain. Doctors often treat the visible blockage. But sometimes, blood flow is still not perfect after the procedure.

Current tools show how wide a pipe is. They do not always show how well blood flows. This is a gap in our knowledge. Patients need more than just a clear pipe. They need a heart that works well again.

The surprising shift

For years, doctors relied on pressure wires. These tools measure blood flow directly. But they are hard to use and expensive. Many hospitals do not have them.

This new study changes the game. It uses a different tool called μQFR. Think of it like a smart map. It calculates flow based on the shape of the pipe. It does not need a pressure wire.

But here is the twist. This new map is just as accurate. It might even be better for predicting your future risk.

What scientists didn't expect

How does this map work? Imagine a traffic jam on a highway. You can see the cars stopped. But you cannot feel the slowdown.

The old tools only see the stopped cars. They miss the slow traffic. The μQFR tool sees the slowdown. It measures the "traffic jam" in your heart.

It looks at the whole heart, not just one pipe. It adds up the problems in all major arteries. This gives a complete picture of your heart's health.

The study snapshot

Researchers looked at 2,428 patients. These people had heart attacks or severe chest pain. They had stents placed in their arteries.

The team calculated the μQFR score for everyone. They split the patients into two groups. One group had a low score. The other had a high score.

They followed these patients for three years. They tracked deaths, new heart attacks, and the need for more surgery.

The results were clear. Patients with a low score did much better. Their risk of major heart problems was lower.

The high-risk group faced a 21% chance of bad events. The low-risk group faced only a 10% chance. That is a huge difference.

Even more importantly, the tool worked the same way for everyone. It did not matter if the doctor used the new map or the old wire. The map was reliable.

This doesn't mean this treatment is available yet.

There is a catch. This tool is not in every hospital yet. It requires special software. Doctors must learn to use it.

The bigger picture

Experts say this is a major step forward. It helps doctors choose the best treatment plan. If the map shows a problem, the doctor can fix it. If it looks good, the doctor can stop there.

This saves time and money. It also reduces the risk of future heart attacks.

If you have heart disease, talk to your doctor. Ask if they use advanced flow tools. These tools help them see the whole picture.

Do not wait for symptoms to return. A simple scan can show hidden risks. Early detection saves lives.

This study proves the tool works. Now, hospitals need to adopt it. Training programs must start soon.

Regulators will review the data. Approval could come in the next few years. Until then, research continues. We want this tool in every clinic.

Your heart deserves the best care. Science is moving fast. Soon, every patient will get this smart map.

Study Details

Study typeRct
Sample sizen = 407
EvidenceLevel 2
Follow-up36.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: The prognostic utility of residual pressure wire-based physiological assessment after percutaneous coronary intervention (PCI) has been demonstrated. OBJECTIVES: The aim of this study was to investigate the prognostic value of the residual global Murray law-based angiographic quantitative flow ratio (μQFR) in an acute coronary syndrome (ACS) population. METHODS: In this post hoc analysis from the FAVOR III China (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients With Coronary Artery Disease) trial, off-line μQFR was computed for 3 major coronary arteries. Residual global μQFR was calculated as the sum of postprocedural μQFR values for treated vessels and preprocedural values for nontreated vessels. ACS patients (including those with ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina) were categorized into high-risk (less than or equal to the cutoff value) and low-risk (greater than the cutoff value) groups according to residual global μQFR. The primary endpoint was 3-year major adverse cardiac events (MACE), the composite of all-cause death, myocardial infarction, or ischemia-driven revascularization. RESULTS: Among 2,428 ACS patients, 2,241 (92.3%) had analyzable μQFR, with a cutoff value of 2.71. High-risk patients (n = 407 [18.2%]) had a greater incidence of 3-year MACE (21.2% vs 10.4%; adjusted HR [aHR]: 1.53; 95% CI: 1.10-2.13; P = 0.01) and MACE excluding periprocedural myocardial infarction (16.2% vs 7.8%; aHR: 1.72; 95% CI: 1.17-2.53; P = 0.006) compared with the low-risk group. The prognostic effect of residual global μQFR was consistent across QFR- and angiography-guided subgroups (P for interaction = 0.35). Patients with low residual ischemia derived the best outcomes after QFR-guided PCI (MACE 8.8% vs 11.9% for angiography-guided PCI; HR: 0.73; 95% CI: 0.55-0.97). CONCLUSIONS: Residual global μQFR is a robust angiographic index for post-PCI ischemia burden and long-term risk stratification. In patients with ACS, QFR-guided PCI achieving low residual global ischemia was associated with the most favorable 3-year prognosis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.